Docetaxel in Combination with Doxorubicin and Cyclophosphamide as Adjuvant Treatment for Early Node-Positive Breast Cancer in the USA: A Cost-Effectiveness and Cost-Utility Analysis

被引：0
|
作者：
Wolowacz, S. E.
Seal, B. S.
Tangirala, M.
机构：
[1] RTI Hlth Solut, Manchester, Lancs, England
[2] Sanofi Aventis Pharmaceut, Bridgewater, NJ USA
[3] Smith Hanley Consulting Grp LLC, Lake Mary, FL USA
来源：
CANCER RESEARCH | 2009年 / 69卷 / 24期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
下载
收藏
页码：622S / 623S
页数：2
相关论文
共 50 条
  • [1] Docetaxel in combination with doxorubicin and cyclophosphamide as adjuvant treatment for early node-positive breast cancer: A cost-effectiveness and cost-utility analysis
    Wolowacz, Sorrel E.
    Cameron, David A.
    Tate, Helen C.
    Bagust, Adrian
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (06) : 925 - 933
  • [2] Cost-effectiveness analysis of adjuvant docetaxel, doxorubicin, and cyclophosphamide (TAC) for node-positive breast cancer: modeling the downstream effects
    Heather-Jane Au
    Kamran Golmohammadi
    Tallal Younis
    Shailendra Verma
    Stephen Chia
    Konrad Fassbender
    Philip Jacobs
    Breast Cancer Research and Treatment, 2009, 114 : 579 - 587
  • [3] Cost-effectiveness analysis of adjuvant docetaxel, doxorubicin, and cyclophosphamide (TAC) for node-positive breast cancer: modeling the downstream effects
    Au, Heather-Jane
    Golmohammadi, Kamran
    Younis, Tallal
    Verma, Shailendra
    Chia, Stephen
    Fassbender, Konrad
    Jacobs, Philip
    BREAST CANCER RESEARCH AND TREATMENT, 2009, 114 (03) : 579 - 587
  • [4] The cost-utility of adjuvant chemotherapy using docetaxel and cyclophosphamide compared with doxorubicin and cyclophosphamide in breast cancer
    Younis, T.
    Rayson, D.
    Skedgel, C.
    CURRENT ONCOLOGY, 2011, 18 (06) : E288 - E296
  • [5] Cost-effectiveness analysis of adjuvant therapy for node positive breast cancer in Korea: docetaxel, doxorubicin and cyclophosphamide (TAC) versus fluorouracil, doxorubicin and cyclophosphamide (FAC)
    Lee, Sang Gyu
    Jee, Young Geon
    Chung, Hyun Chul
    Kim, Sung-Bae
    Ro, Jungsil
    Im, Young-Hyuck
    Im, Seock-Ah
    Seo, Jae Hong
    BREAST CANCER RESEARCH AND TREATMENT, 2009, 114 (03) : 589 - 595
  • [6] Cost-effectiveness of adjuvant chemotherapy in node-positive breast cancer
    Orsi, Cecilia
    Caccese, Erminia
    Cecchi, Michele
    Messori, Andrea
    Tendi, Enrico
    PHARMACY WORLD & SCIENCE, 2007, 29 (05): : 453 - 454
  • [7] COST-EFFECTIVENESS OF DOCETAXEL PLUS CYCLOPHOSPHAMIDE VERSUS DOXORUBICIN PLUS CYCLOPHOSPHAMIDE IN THE ADJUVANT TREATMENT OF OPERABLE BREAST CANCER
    Jones, S.
    Chen, L.
    Tangirala, M.
    Asmar, L.
    Airia, P.
    Thompson, M. F.
    VALUE IN HEALTH, 2009, 12 (03) : A45 - A45
  • [8] Cost–effectiveness analysis of adjuvant therapy for node positive breast cancer in Korea: docetaxel, doxorubicin and cyclophosphamide (TAC) versus fluorouracil, doxorubicin and cyclophosphamide (FAC)
    Sang Gyu Lee
    Young Geon Jee
    Hyun Chul Chung
    Sung-Bae Kim
    Jungsil Ro
    Young-Hyuck Im
    Seock-Ah Im
    Jae Hong Seo
    Breast Cancer Research and Treatment, 2009, 114 : 589 - 595
  • [9] Erratum to: Cost-effectiveness of adjuvant chemotherapy with cyclophosphamide + methotrexate + fluorouracil in patients with node-positive breast cancer
    A. Messori
    P. Becagli
    S. Trippoli
    E. Tendi
    European Journal of Clinical Pharmacology, 1997, 51 : 427 - 427
  • [10] Cost-utility analysis of 21-gene assay for node-positive early breast cancer
    Masucci, L.
    Torres, S.
    Eisen, A.
    Trudeau, M.
    Tyono, I
    Saunders, H.
    Chan, K. W.
    Isaranuwatchai, W.
    CURRENT ONCOLOGY, 2019, 26 (05) : 307 - 318
12345